{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T10:47:22Z","timestamp":1776509242601,"version":"3.51.2"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00417-025-07040-z","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T01:57:13Z","timestamp":1768010233000},"page":"1345-1353","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of macular atrophy in type 3 macular neovascularization cases: a follow-up of over 7 years"],"prefix":"10.1007","volume":"264","author":[{"given":"Junichiro","family":"Honjo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1796-9232","authenticated-orcid":false,"given":"Ryo","family":"Mukai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanako","family":"Itagaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koki","family":"Norikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihito","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuju","family":"Sekiryu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,10]]},"reference":[{"key":"7040_CR1","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1001\/archopht.122.4.477","volume":"122","author":"N Congdon","year":"2004","unstructured":"Congdon N, O\u2019Colmain B, Klaver CCW et al (2004) Causes and prevalence of visual impairment among adults in the united States. Arch Ophthalmol 122:477\u2013485. https:\/\/doi.org\/10.1001\/archopht.122.4.477","journal-title":"Arch Ophthalmol"},{"key":"7040_CR2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.22608\/APO.2017251","volume":"6","author":"JB Jonas","year":"2017","unstructured":"Jonas JB, Cheung CMG, Panda-Jonas S (2017) Updates on the epidemiology of age-related macular degeneration. Asia Pac J Ophthalmol (Phila) 6:493\u2013497. https:\/\/doi.org\/10.22608\/APO.2017251","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"7040_CR3","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ophtha.2013.08.015","volume":"121","author":"JE Grunwald","year":"2014","unstructured":"Grunwald JE, Daniel E, Huang J et al (2014) Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 121:150\u2013161. https:\/\/doi.org\/10.1016\/j.ophtha.2013.08.015","journal-title":"Ophthalmology"},{"key":"7040_CR4","doi-asserted-by":"publisher","unstructured":"Cho HJ, Yoo SG, Kim HS et al (2015) Risk factors for geographic atrophy after intravitreal Ranibizumab injections for retinal angiomatous proliferation. Am J Ophthalmol 159. https:\/\/doi.org\/10.1016\/j.ajo.2014.10.035. 285\u2009\u2013\u200992.e1","DOI":"10.1016\/j.ajo.2014.10.035"},{"key":"7040_CR5","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ophtha.2019.08.023","volume":"127","author":"MC Gillies","year":"2020","unstructured":"Gillies MC, Hunyor AP, Arnold JJ et al (2020) Macular atrophy in neovascular age-related macular degeneration: A randomized clinical trial comparing Ranibizumab and Aflibercept (RIVAL study). Ophthalmology 127:198\u2013210. https:\/\/doi.org\/10.1016\/j.ophtha.2019.08.023","journal-title":"Ophthalmology"},{"key":"7040_CR6","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/j.ophtha.2020.06.019","volume":"127","author":"KL Spooner","year":"2020","unstructured":"Spooner KL, Fraser-Bell S, Cozzi M et al (2020) Macular atrophy incidence and progression in eyes with neovascular age-related macular degeneration treated with vascular endothelial growth factor inhibitors using a treat-and-extend or a pro re nata regimen: four-year results of the MANEX study. Ophthalmology 127:1663\u20131673. https:\/\/doi.org\/10.1016\/j.ophtha.2020.06.019","journal-title":"Ophthalmology"},{"key":"7040_CR7","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.survophthal.2018.05.005","volume":"63","author":"RF Spaide","year":"2018","unstructured":"Spaide RF, Ooto S, Curcio CA (2018) Subretinal drusenoid deposits AKA pseudodrusen. Surv Ophthalmol 63:782\u2013815. https:\/\/doi.org\/10.1016\/j.survophthal.2018.05.005","journal-title":"Surv Ophthalmol"},{"key":"7040_CR8","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.oret.2019.09.016","volume":"4","author":"M Pfau","year":"2020","unstructured":"Pfau M, M\u00f6ller PT, K\u00fcnzel SH et al (2020) Type 1 choroidal neovascularization is associated with reduced localized progression of atrophy in age-related macular degeneration. Ophthalmol Retina 4:238\u2013248. https:\/\/doi.org\/10.1016\/j.oret.2019.09.016","journal-title":"Ophthalmol Retina"},{"key":"7040_CR9","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00417-017-3888-2","volume":"256","author":"W Fan","year":"2018","unstructured":"Fan W, Abdelfattah NS, Uji A et al (2018) Subfoveal choroidal thickness predicts macular atrophy in age-related macular degeneration: results from the TREX-AMD trial. Graefes Arch Clin Exp Ophthalmol 256:511\u2013518. https:\/\/doi.org\/10.1007\/s00417-017-3888-2","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7040_CR10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s10384-023-00981-0","volume":"67","author":"T Sawada","year":"2023","unstructured":"Sawada T, Yasukawa T, Imaizumi H et al (2023) Subtype prevalence and baseline visual acuity by age in Japanese patients with neovascular age-related macular degeneration. Jpn J Ophthalmol 67:149\u2013155. https:\/\/doi.org\/10.1007\/s10384-023-00981-0","journal-title":"Jpn J Ophthalmol"},{"key":"7040_CR11","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/j.ophtha.2015.03.027","volume":"122","author":"M Lindner","year":"2015","unstructured":"Lindner M, B\u00f6ker A, Mauschitz MM et al (2015) Directional kinetics of geographic atrophy progression in age-related macular degeneration with foveal sparing. Ophthalmology 122:1356\u20131365. https:\/\/doi.org\/10.1016\/j.ophtha.2015.03.027","journal-title":"Ophthalmology"},{"key":"7040_CR12","doi-asserted-by":"publisher","first-page":"9497","DOI":"10.1167\/iovs.11-8346","volume":"52","author":"UEK Wolf-Schnurrbusch","year":"2011","unstructured":"Wolf-Schnurrbusch UEK, Wittwer VV, Ghanem R et al (2011) Blue-light versus green-light autofluorescence: lesion size of areas of geographic atrophy. Invest Ophthalmol Vis Sci 52:9497\u20139502. https:\/\/doi.org\/10.1167\/iovs.11-8346","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"7040_CR13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10384-012-0215-7","volume":"57","author":"M Saito","year":"2013","unstructured":"Saito M, Iida T, Kano M (2013) Two-year results of combined intravitreal anti-VEGF agents and photodynamic therapy for retinal angiomatous proliferation. Jpn J Ophthalmol 57:211\u2013220. https:\/\/doi.org\/10.1007\/s10384-012-0215-7","journal-title":"Jpn J Ophthalmol"},{"key":"7040_CR14","doi-asserted-by":"crossref","unstructured":"Alexandros A, Rouvas TD, Papakostas ID, Ladas I Vergados (2008) Enlargement of the hypofluorescent post photodynamic therapy treatment spot after a combination of photodynamic therapy with an intravitreal injection of bevacizumab for retinal angiomatous proliferation. Graefe\u2019s archive for clinical and experimental ophthalmology. 246(2):315\u2013318","DOI":"10.1007\/s00417-007-0669-3"},{"key":"7040_CR15","doi-asserted-by":"crossref","unstructured":"Sutter FK, Kurz-Levin MM, Fleischhauer J, B\u00f6sch MM, Barthelmes D, Helbig H (2006) Macular atrophy after combined intravitreal triamcinolone acetonide (IVTA) and photodynamic therapy (PDT) for retinal angiomatous proliferation (RAP). Klinische Monatsblatter fur Augenheilkunde. May; 223 (5); 376-8","DOI":"10.1055\/s-2006-926564"},{"issue":"3","key":"7040_CR16","first-page":"830","volume":"43","author":"US-ES Michels","year":"2002","unstructured":"Michels US-ES, Barbazetto I, Horst Laqua (2002) Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Visual Sci Mar 43(3):830\u2013841","journal-title":"Invest Ophthalmol Visual Sci Mar"},{"key":"7040_CR17","doi-asserted-by":"crossref","unstructured":"Laurence Postelmans, Brigitte Pasteels, Pascale Coquelet, Hind El Ouardighi, Claire Verougstraete, Ursula Schmidt-Erfurth (2004) Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females. Am J Ophthalmol 138(5):803\u20138","DOI":"10.1016\/j.ajo.2004.06.033"},{"key":"7040_CR18","doi-asserted-by":"publisher","first-page":"e540","DOI":"10.1111\/aos.14631","volume":"99","author":"HJ Cho","year":"2021","unstructured":"Cho HJ, Park SM, Kim J et al (2021) Progression of macular atrophy in patients undergoing anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration. Acta Ophthalmol 99:e540\u2013e546. https:\/\/doi.org\/10.1111\/aos.14631","journal-title":"Acta Ophthalmol"},{"key":"7040_CR19","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1167\/iovs.15-18837","volume":"57","author":"J Baek","year":"2016","unstructured":"Baek J, Lee JH, Kim JY, Kim NH, Lee WK (2016) Geographic atrophy and activity of neovascularization in retinal angiomatous proliferation. Invest Ophthalmol Vis Sci 57:1500\u20131505. https:\/\/doi.org\/10.1167\/iovs.15-18837","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"7040_CR20","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000520595","volume":"245","author":"S Blazaki","year":"2022","unstructured":"Blazaki S, Blavakis E, Smoustopoulos G et al (2022) Progression of macular atrophy in patients receiving long-term anti-VEGF therapy for age-related macular degeneration: real-life data. Ophthalmologica 245:152\u2013160. https:\/\/doi.org\/10.1159\/000520595","journal-title":"Ophthalmologica"},{"key":"7040_CR21","doi-asserted-by":"publisher","first-page":"e757","DOI":"10.1111\/aos.13157","volume":"94","author":"MR Munk","year":"2016","unstructured":"Munk MR, Ceklic L, Ebneter A, Huf W, Wolf S, Zinkernagel MS (2016) Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration. Acta Ophthalmol 94:e757\u2013e764. https:\/\/doi.org\/10.1111\/aos.13157","journal-title":"Acta Ophthalmol"},{"key":"7040_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/BF00416865","volume":"192","author":"SS Hayreh","year":"1974","unstructured":"Hayreh SS (1974) Submacular choroidal vascular pattern. Experimental fluorescein fundus angiographic studies. Albrecht Von Graefes Arch Klin Exp Ophthalmol 192:181\u2013196. https:\/\/doi.org\/10.1007\/BF00416865","journal-title":"Albrecht Von Graefes Arch Klin Exp Ophthalmol"},{"key":"7040_CR23","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ajo.2003.09.042","volume":"137","author":"HE Grossniklaus","year":"2004","unstructured":"Grossniklaus HE, Green WR (2004) Choroidal neovascularization. Am J Ophthalmol 137:496\u2013503. https:\/\/doi.org\/10.1016\/j.ajo.2003.09.042","journal-title":"Am J Ophthalmol"},{"key":"7040_CR24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.ajo.2010.04.018","volume":"150","author":"V Manjunath","year":"2010","unstructured":"Manjunath V, Taha M, Fujimoto JG, Duker JS (2010) Choroidal thickness in normal eyes measured using cirrus HD optical coherence tomography. Am J Ophthalmol 150:325-329.e1. https:\/\/doi.org\/10.1016\/j.ajo.2010.04.018","journal-title":"Am J Ophthalmol"},{"key":"7040_CR25","doi-asserted-by":"publisher","first-page":"7812","DOI":"10.1167\/iovs.13-12284","volume":"54","author":"JY Lee","year":"2013","unstructured":"Lee JY, Lee DH, Lee JY, Yoon YH (2013) Correlation between subfoveal choroidal thickness and the severity or progression of nonexudative age-related macular degeneration. Invest Ophthalmol Vis Sci 54:7812\u20137818. https:\/\/doi.org\/10.1167\/iovs.13-12284","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"7040_CR26","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3928\/23258160-20160707-02","volume":"47","author":"AT Legocki","year":"2016","unstructured":"Legocki AT, Adhi M, Weber ML, Duker JS (2016) Choroidal morphology and vascular analysis in eyes with neovascular age-related macular degeneration using spectral-domain optical coherence tomography. Ophthalmic Surg Lasers Imaging Retina 47:618\u2013625. https:\/\/doi.org\/10.3928\/23258160-20160707-02","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"7040_CR27","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1097\/IAE.0000000000000139","volume":"34","author":"S Mrejen","year":"2014","unstructured":"Mrejen S, Spaide RF (2014) The relationship between pseudodrusen and choroidal thickness. Retina 34:1560\u20131566. https:\/\/doi.org\/10.1097\/IAE.0000000000000139","journal-title":"Retina"},{"key":"7040_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2012.11.001","author":"JH Kim","year":"2013","unstructured":"Kim JH, Kim JR, Kang SW, Kim SJ, Ha HS (2013) Thinner choroid and greater drusen extent in retinal angiomatous proliferation than in typical exudative age-related macular degeneration. Am J Ophthalmol. https:\/\/doi.org\/10.1016\/j.ajo.2012.11.001","journal-title":"Am J Ophthalmol"},{"key":"7040_CR29","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1167\/iovs.64.13.16","volume":"64","author":"M Shen","year":"2023","unstructured":"Shen M, Zhou H, Lu J et al (2023) Choroidal changes after anti-VEGF therapy in AMD eyes with different types of macular neovascularization using swept-source OCT angiography. Invest Ophthalmol Vis Sci 64:16. https:\/\/doi.org\/10.1167\/iovs.64.13.16","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"7040_CR30","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1007\/s00417-015-3260-3","volume":"254","author":"C Yun","year":"2016","unstructured":"Yun C, Oh J, Ahn J et al (2016) Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 254:1693\u20131702. https:\/\/doi.org\/10.1007\/s00417-015-3260-3","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7040_CR31","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1159\/000526044","volume":"245","author":"J Hoshino","year":"2022","unstructured":"Hoshino J, Matsumoto H, Mukai R, Nakamura K, Akiyama H (2022) Intravitreal aflibercept versus brolucizumab for treatment-naive neovascular age-related macular degeneration with type 1 macular neovascularization: comparison of short-term outcomes. Ophthalmologica 245:413\u2013420. https:\/\/doi.org\/10.1159\/000526044","journal-title":"Ophthalmologica"},{"key":"7040_CR32","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","volume":"135","author":"A Koh","year":"2017","unstructured":"Koh A, Lai TYY, Takahashi K et al (2017) Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial. JAMA Ophthalmol 135:1206\u20131213. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.4030","journal-title":"JAMA Ophthalmol"},{"key":"7040_CR33","doi-asserted-by":"publisher","first-page":"1141077","DOI":"10.3389\/fphar.2023.1141077","volume":"14","author":"M Fallico","year":"2023","unstructured":"Fallico M, Macchi I, Maugeri A et al (2023) Anti-vascular endothelial growth factor monotherapy or combined with verteporfin photodynamic therapy for retinal angiomatous proliferation: a systematic review with meta-analysis. Front Pharmacol 14:1141077. https:\/\/doi.org\/10.3389\/fphar.2023.1141077","journal-title":"Front Pharmacol"},{"key":"7040_CR34","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/IAE.0000000000002793","volume":"41","author":"R Mukai","year":"2021","unstructured":"Mukai R, Matsumoto H, Miyakubo T, Akiyama H (2021) Reduced vascular density in the choroid after treatment with photodynamic therapy combined with aflibercept in patients with polypoidal choroidal vasculopathy. Retina 41:156\u2013161. https:\/\/doi.org\/10.1097\/IAE.0000000000002793","journal-title":"Retina"},{"key":"7040_CR35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1167\/iovs.65.3.18","volume":"65","author":"E Borrelli","year":"2024","unstructured":"Borrelli E, Barresi C, Ricardi F et al (2024) Distinct pathways of macular atrophy in type 3 macular neovascularization associated with AMD. Invest Ophthalmol Vis Sci 65:18. https:\/\/doi.org\/10.1167\/iovs.65.3.18","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-07040-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-025-07040-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-07040-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T10:17:56Z","timestamp":1776507476000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-025-07040-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,10]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["7040"],"URL":"https:\/\/doi.org\/10.1007\/s00417-025-07040-z","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,10]]},"assertion":[{"value":"27 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving human participants were conducted in accordance with the ethical standards of the institutional research committee (The Institutional Review Board and the Ethics Committee of Fukushima Medical University) and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The requirement for informed consent was waived due to the retrospective study design. This article does not contain any studies with animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Sekiryu T. received grants from Novartis Pharma, Pfizer, Japan Alcon, Wakamoto Pharmaceutical, HOYA, Bayer Pharmaceuticals, Santen Pharmaceutical, Senju Pharmaceutical, AMO Japan, and Kowa; received lecturing and travel fees from Novartis Pharma, Chugai Pharmaceutical, Akura, Abbott, Alcon Pharma, Santen Pharmaceutical, and Senju Pharmaceutical; and received a consulting fee from Allergan Japan. Mukai R. received lecturing and travel fees from Alcon Pharma, Chugai Pharmaceutical, and Senju Pharmaceutical. Honjo J. received lecturing and travel fees from Chugai Pharmaceutical, and Senju Pharmaceutical. Itagaki K, Tanaka K, Norikawa K, Kato Y, and Kasai A declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests\u00a0<!--Emphasis Type='Bold' removed-->and Funding"}}]}}